Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Raises $47.4M in Public Offering

NEW YORK (GenomeWeb News) – Clinical Data has raised gross proceeds of $47.4 million through the sale of 2,750,000 newly issued shares of its common stock at a price of $17.25 per share.

According to a filing with the US Securities and Exchange Commission filed today, net proceeds from the offering are approximately $44.1 million. The underwriters of the offering have an option to purchase an additional 412,500 shares, which would bring total gross proceeds to $54.6 million. The offering is expected to close on Nov. 2, the firm said.

Clinical Data intends to use the funds to support preparation of its application with the US Food and Drug Administration for approval of its vilazodone drug for depression, as well as Phase III studies of its Stedivaze drug for cardiac stress imaging. It also said that it may use the proceeds for other drug development efforts and general corporate purposes.

In addition to its drug business, Clinical Data's PGx Health decision manufactures pharmacogenomic tests.

In early Wednesday trade on the Nasdaq, shares of Clinical Data were down 10 percent at $17.02.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.